A study to evaluate the effectiveness and safety of Apremilast in subjects with active psoriatic arthritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001590-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of apremilast 30 mg twice daily (BID) monotherapy, compared with placebo, over 24 weeks of treatment, with the primary analysis at Wk 16, in subjects with active psoriatic arthritis


Critère d'inclusion

  • Psoriatic Arthritis